Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma - Takeaways - MDSpire

Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma

  • By

  • Xiaoxing Liu

  • Shanshan Li

  • Min Zhou

  • Ning Ding

  • Jinzhong Chen

  • Ning Zhou

  • January 16, 2026

  • 0 min

Share

  • 1

    Lung adenocarcinoma (LUAD) is a leading cause of cancer death, with low five-year survival rates despite advances in treatment.

  • 2

    N6-methyladenosine (m6A) modification plays a crucial role in LUAD progression, prognosis, and therapy response.

  • 3

    Aberrant m6A expression is linked to tumor metabolic reprogramming and immune evasion in LUAD.

  • 4

    This study aims to develop a genetic risk model based on m6A-related genes to predict LUAD prognosis and guide therapy.

  • 5

    Findings are expected to enhance understanding of m6A modifications in LUAD and improve immunotherapy strategies.

Original Source(s)

Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma

  • by Xiaoxing Liu, Shanshan Li, Min Zhou, Ning Ding, Jinzhong Chen, Ning Zhou

  • January 16, 2026

Related Content

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • by

  • June 1, 2026

  • 5 min
Exercise interventions for depressive symptoms in adults with lung and digestive cancer: a meta-analysis of randomized controlled trials

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients